Business · Companies · 3 hrs ago
Entropy Neurodynamics granted South African patent for psilocin forms
Entropy Neurodynamics was granted a South African patent for specific crystalline forms of psilocin, a substance linked to psilocybin.
The patent also covers related pharmaceutical compositions and ways to prepare them.
The grant follows a corresponding Australian patent issued earlier in 2026.
Entropy says these forms may offer improved stability, solubility and consistency compared with conventional psilocin formulations.
The patent adds protection for its TRP-8803 program, which uses controlled intravenous psilocin treatment, and complements other parts of the company’s intellectual property portfolio.
The South African patent runs for 20 years from September 12, 2023, subject to renewal fees.
Entropy says it is pursuing further patent applications in jurisdictions including the United States, and that its expanding portfolio could support future clinical development, licensing and partnerships.
Entropy Neurodynamics has been granted a South African patent covering proprietary crystalline forms of psilocin.
The patent also covers associated pharmaceutical compositions and preparation methods.
It follows the grant of a corresponding Australian patent earlier in 2026.
The company said the patent supports its intellectual property portfolio and development of its TRP-8803 program.
The South African patent has a 20-year term from September 12, 2023, subject to renewal fees.
- Who
- Entropy Neurodynamics.
- What
- It was granted a South African patent covering crystalline forms of psilocin, related pharmaceutical compositions and preparation methods.
- When
- The grant date is not stated. The patent follows a corresponding Australian patent granted earlier in 2026.
- Where
- South Africa.
- Why
- The patent expands the company’s intellectual property protection for psilocin technology and supports development of TRP-8803.
This story does not have two clearly opposing sides.
The 20-year term of the South African patent began, subject to applicable renewal fees.
A corresponding Australian patent was granted.
Entropy Neurodynamics was granted the South African patent.
- Patent coverage
- Crystalline forms of psilocin, associated pharmaceutical compositions and preparation methods
- South African patent term
- 20 years from September 12, 2023, subject to renewal fees
- Corresponding Australian patent
- Granted earlier in 2026
- Lead program
- TRP-8803
What people are saying
Our IP strategy is focused on building a broad and defensible portfolio that protects multiple aspects of our proprietary psilocin technology, from formulation and delivery through to dosing methodologies and therapeutic applications
With patents now granted in Australia and South Africa, and additional applications progressing across key international jurisdictions, we are systematically building a global IP portfolio designed to support the long-term commercial potential of TRP-8803.